Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ustekinumab versus vedolizumab as first-line biologic treatment for Crohn's disease
ChiCTR2500095409Phase 4Recruiting
- Sponsor
- Shanghai Tenth People's Hospital
- Start
- Jan 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in Crohn's disease comparing UST group with VDZ group (2 arms). Primary endpoint: Crohn's disease activity index. Started Jan 2025; status: recruiting.
02
Drugs
ustekinumabvedolizumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on ChiCTR2500095409.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500095409.